Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran.
Solomon also updates on their lead candidate, SLN124, which is being developed to treat iron overload disorders.